Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index

被引:67
作者
Guzzo, Thomas J.
Dluzniewski, Paul
Orosco, Ryan
Platz, Elizabeth A.
Partin, Alan W.
Han, Misop
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
LIFE-EXPECTANCY; CANCER; SURVIVAL; AGE; MANAGEMENT; MORBIDITY; CARCINOMA; ACCURACY; NOMOGRAM; DISEASE;
D O I
10.1016/j.urology.2010.02.069
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Prostate cancer treatment should depend on the characteristics of a patient's prostate cancer as well as overall health status. A possible adverse consequence of poor patient selection is a lack of benefit because of premature death from another cause. We evaluated the association between perioperative comorbidity and risk of death from causes other than prostate cancer in men who underwent radical prostatectomy (RP). METHODS We conducted a retrospective cohort study of 14,052 men who underwent RP from 1983 to 2006. The Charlson Comorbidity Index (CCI) score was calculated using the discharge records for the prostatectomy hospitalization. Mortality status and cause of death were obtained via chart review and searches of national databases. Cox proportional hazards regression was used to estimate the hazard ratio (HR) of death from causes other than prostate cancer after RP by CCI score (0, 1, 2+). RESULTS The median age at RP was 58.1 years. The median follow-up was 7.6 years (interquartile range 4.3-11.5). Of 849 deaths, 599 (70.6%) resulted from causes other than prostate cancer. On multivariable analysis, men with a CCI >= 2 had a statistically significantly higher risk of death from causes other than prostate cancer compared with those with lower CCI scores (HR 2.18, 95% CI 1.30-3.64, P = .0003). CONCLUSIONS Greater perioperative comorbidity was associated with a higher risk of death from causes other than prostate cancer in men who underwent RP. Physicians should consider using a standardized tool to assess perioperative comorbidities to enhance appropriate recommendation for surgical treatment. UROLOGY 76: 553-558, 2010. (c) 2010 Elsevier Inc.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 30 条
  • [1] 20-year outcomes following conservative management of clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Fine, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2095 - 2101
  • [2] The impact of co-morbidity on life expectancy among men with localized prostate cancer
    Albertsen, PC
    Fryback, DG
    Storer, BE
    Kolon, TF
    Fine, J
    [J]. JOURNAL OF UROLOGY, 1996, 156 (01) : 127 - 132
  • [3] Is there an optimal comorbidity index for prostate cancer?
    Alibhai, Shabbir M. H.
    Leach, Marc
    Tomlinson, George A.
    Krahn, Murray D.
    Fleshner, Neil E.
    Naglie, Gary
    [J]. CANCER, 2008, 112 (05) : 1043 - 1050
  • [4] Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of national cancer institute of Canada clinical trials group trials
    Asmis, Timothy R.
    Ding, Keyue
    Seymour, Lesley
    Shepherd, Frances A.
    Leighl, Natasha B.
    Winton, Tim L.
    Whitehead, Marlo
    Spaans, Johanna N.
    Graham, Barbara C.
    Goss, Glenwood D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 54 - 59
  • [5] Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent
    Boulos, DL
    Groome, PA
    Brundage, MD
    Siemens, DR
    Mackillop, WJ
    Heaton, JPW
    Schulze, KM
    Rohland, SL
    [J]. CANCER, 2006, 106 (08) : 1804 - 1814
  • [6] BOVA GS, 1993, MODERN PATHOL, V6, P201
  • [7] Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer
    Draisma, G
    Boer, R
    Otto, SJ
    van der Cruijsen, IW
    Damhuis, RAM
    Schröder, FH
    de Koning, HJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) : 868 - 878
  • [8] Predicting an optimal outcome after radical prostatectomy: The trifecta nomogram
    Eastham, James A.
    Scardino, Peter T.
    Kattan, Michael W.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (06) : 2207 - 2210
  • [9] Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy
    Froehner, M
    Koch, R
    Litz, RJ
    Oehlschlaeger, S
    Hakenberg, OW
    Wirth, MP
    [J]. EUROPEAN UROLOGY, 2005, 47 (02) : 190 - 195
  • [10] Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy
    Froehner, M
    Koch, R
    Litz, R
    Heller, A
    Oehlschlaeger, S
    Wirth, MP
    [J]. UROLOGY, 2003, 62 (04) : 698 - 701